Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients
(World News Science)

NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events XIRIUS expansion study planned to initiate in Q4 2018 Detailed results to be presented at R&D day on September 24, 2018 WALTHAM, Mass. and LONDON, Sept. 22, 2018 (GLOBE NEWSWIRE) --...